A group of experts in rheumatology and dermatology has identified many unmet needs in the care of patients with psoriatic arthritis and offered potential solutions. But do their recommendations go far enough?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Helliwell, P. et al. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.22404.
Kane, D. & Pathare, S. Early psoriatic arthritis. Rheum. Dis. Clin. North Am. 31, 641–657 (2005).
Kavanaugh, A. F., Ritchlin, C. T. & GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J. Rheumatol. 33, 1417–1421 (2006).
Englbrecht, M. et al. Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives. Arthritis Care Res. 62, 977–983 (2010).
Coates, L. C. et al. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum. 65, 1504–1509 (2013).
Fagerli, K. M. et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann. Rheum. Dis. 72, 1840–1844 (2013).
Wu, N., Lee, Y. C., Shah, N. & Harrison, D. J. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Clin. Ther. 36, 1231–1241.e3 (2014).
Dandorfer, S. W., Rech, J., Manger, B., Schett, G. & Englbrecht, M. Differences in the patient's and the physician's perspective of disease in psoriatic arthritis. Semin. Arthritis Rheum. 42, 32–41 (2012).
Husted, J. A. et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res. (Hoboken) 63, 1729–1735 (2011).
Di Minno, M. N. et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann. Rheum. Dis. 73, 1157–1162 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares that he has acted as a consultant for Amgen, Abbvie, Janssen and UCB, and received funding for research from Amgen and UCB.
Rights and permissions
About this article
Cite this article
Ritchlin, C. Closing the gap in psoriatic arthritis. Nat Rev Rheumatol 10, 704–705 (2014). https://doi.org/10.1038/nrrheum.2014.169
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2014.169
This article is cited by
-
Disease Modification in Psoriatic Arthritis
Current Treatment Options in Rheumatology (2018)